233 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1520)
- Addiction (14)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (26)
- Blood Disorders (33)
- Bone & Muscle (8)
- Cancer (552)
- Child Development (4)
- COVID-19 (Coronavirus) (28)
- Critical Illness (1)
- Diabetes (15)
- Ear, Nose and Throat (5)
- Endocrine & Metabolic Disease (10)
- Eye (7)
- Gastrointestinal and Digestive Diseases (23)
- Hair and Skin Disorders (1)
- Headaches (5)
- Healthy Volunteers (143)
- Heart Disease (110)
- Infectious Disease (38)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (40)
- Lung Disease (29)
- Meniere's Disease (1)
- Neurological Disorders (134)
- Nutrition (5)
- Obesity (1)
- Obstetrics & Gynecology (45)
- Pain Management (1)
- Pediatrics (86)
- Psychiatric Disorders (60)
- Rehabilitation (7)
- Stroke (5)
- Surgery (7)
- Transplant (36)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 6 of 6
Condition: Liver Disease / Liver Failure
Investigator: Elizabeth Verna, MD
Status: Closed
The purpose of this research study is to determine if an investigational drug, VS-01, will help in the treatment of acute-on-chronic liver failure (ACLF) compared to supportive care (standard of therapy). ACLF is a potentially life-threatening condition characterized by a group of signs that occur together (syndrome) in patients with a late stage of…
Condition: Neurological Disorders / Dementia
Investigator: Sairam Geethanath, PhD
Status: Closed
A significant focus of healthcare research is aimed at biomarker discoveries in brain and heart diseases in particular, and their impact on the human body in general. MRI is a key component in these healthcare services. It provides a non-invasive and non-ionizing approach to diagnose pathologies along with significant internal and external contrast…
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid…
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a research study for persons with memory problems that examines the utility of performing positron emission tomography (PET) scans for the brain amyloid protein found in Alzheimer's disease.
Condition: Neurological Disorders / Dementia
Investigator: Edward Huey, MD
Status: Closed
Columbia Medical Center is recruiting for a study to test whether the drug oxytocin can improve symptoms of emotion and behavior (e.g. apathy) in people with frontotemporal dementia. The study will last for up to 24 weeks (6 months). This is a crossover study, which means that each participant will receive both oxytocin and placebo (medically inactive…
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who…